Johnson & Johnson Reaches Talc Settlement and Hits Record Highs
Johnson & Johnson reached a $5.5 billion settlement to resolve ovarian cancer litigation tied to its talc-based products, lifting the stock to record highs before it lost some momentum later in the day. The deal involves paying $3 billion by 2027 and is contingent on at least 95% of claimants participating across approximately 76,000 cases. Jim Cramer noted that while this settlement was a major milestone for J&J, it's not the primary reason to invest in the stock. He highlighted its strong pharmaceuticals and medical technology divisions as key drivers behind its nearly 30% year-to-date gain compared to the S&P 500’s roughly 8.5%. The company is on track to become a top oncology player by 2030, with blockbuster drugs like Darzalex generating over $4.2 billion in Q2 sales. J&J also recently received FDA approval for Icotyde and its robotic surgical system Ottava, both of which are expected to drive future growth.
Tickers: $JNJ
Topics: Johnson & Johnson ovarian cancer settlement talc litigation